Skip to content

Screening Women at High Genetic Risk for Ovarian Cancer

The UK Familial Ovarian Cancer Screening Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00033488
Enrollment
5000
Registered
2003-01-27
Start date
2000-09-30
Completion date
2010-03-31
Last updated
2013-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Keywords

ovarian epithelial cancer

Brief summary

RATIONALE: Screening tests may help doctors detect cancer cells early and plan more effective treatment for ovarian cancer. PURPOSE: Screening trial to determine the best procedure to detect ovarian cancer in women who have a high genetic risk for developing ovarian cancer.

Detailed description

OBJECTIVES: * Determine an optimal screening procedure for ovarian cancer, in terms of the most appropriate screening test, criteria for interpretation of results, and screening intervals, in women at high genetic risk for developing ovarian cancer. * Determine the physical morbidity and the resource implications associated with ovarian cancer screening in these women. * Assess the feasibility of screening this high-risk population in terms of compliance rates. OUTLINE: Patients undergo transvaginal ultrasonography of the ovaries (scheduled for the early follicular phase, day 3-6 of the menstrual cycle) and CA 125 measurement annually. Blood samples are collected every 4 months for analysis of CA 125 levels and novel markers. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 5,000 patients will be accrued for this study.

Interventions

OTHERcytology specimen collection procedure

Sponsors

University College London Hospitals
Lead SponsorOTHER

Study design

Primary purpose
SCREENING

Eligibility

Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * First-degree relative (mother, sister, or daughter) of an affected member of a high-risk family defined as one of the following: * Family containing 2 or more individuals with ovarian cancer who are connected by first-degree relationships * Family containing 1 individual with ovarian cancer and 1 individual with breast cancer and under 50 years of age at the time of diagnosis who are connected by first-degree relationships * Family containing 1 individual with ovarian cancer and 2 individuals with breast cancer and under 60 years of age at the time of diagnosis who are connected by first-degree relationships * Family containing an affected individual with a mutation of one of the known ovarian cancer predisposing genes * Family containing 3 individuals with colorectal cancer with at least 1 individual under 50 years of age at time of diagnosis and 1 individual with ovarian cancer who are connected by first-degree relationships * Families where affected relatives are related by second-degree relationships through an unaffected intervening male relative who has an affected daughter are allowed PATIENT CHARACTERISTICS: Age: * 35 and over Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * No prior bilateral oophorectomy Other: * No concurrent participation in other ovarian cancer screening trials

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026